CRISPR Screens Identify Cholesterol Biosynthesis as a Therapeutic Target on Stemness and Drug Resistance of Colon Cancer

To identify genetic vulnerabilities of colon cancer, investigators performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon cancer stem cells-enriched spheroids.